The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The prognosis of NF1 mutations in newly diagnosed AML: A single-center retrospective study.
 
Mohammad Telfah
No Relationships to Disclose
 
Haitham Abdelhakim
No Relationships to Disclose
 
Nicole Balmaceda
No Relationships to Disclose
 
Eyad Gharaibeh
No Relationships to Disclose
 
Andrew K. Godwin
No Relationships to Disclose
 
Ziyan Y. Pessetto
Honoraria - QIAGEN
Travel, Accommodations, Expenses - Illumina
 
Joseph McGuirk
Honoraria - Kite, a Gilead company; Novartis
Consulting or Advisory Role - Kite, a Gilead company
Speakers' Bureau - Kite/Gilead
Research Funding - Astellas Pharma (Inst); Bellicum Pharmaceuticals (Inst); Fresenius Biotech (Inst); Gamida Cell (Inst); Kite, a Gilead company (Inst); Novartis (Inst); Novartis (Inst); Pluristem Therapeutics (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Tara L. Lin
Honoraria - Jazz Pharmaceuticals
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bio-Path Holdings, Inc (Inst); Celator (Inst); Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Imago Pharma (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Mateon Therapeutics (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Prescient Therapeutics (Inst); Seagen (Inst); Tolero Pharmaceuticals (Inst); Trovagene (Inst)